Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea
International Journal of Hematology, 05/24/2012Kim D et al.
Treatment adherence in the early treatment period was one of the important independent predictors of favorable long–term outcome. Durable cytogenetic and molecular responses were maintained in a majority of patients treated with optimal dose intensity.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.